This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singer, S. Articles by Antonescu, C. R. Search for Related Content PubMed PubMed Citation Articles by Singer, S. Articles by Antonescu, C. R.

Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated Liposarcoma

¹ Sarcoma Biology Laboratory, Sarcoma Disease Management Program, Department of Surgery, ² Sarcoma Disease Management Program, Department of Pathology, ³ Laboratory of New Drug Development, Department of Medicine, and ⁴ Computational Biology Center, Memorial Sloan-Kettering Cancer Center and ⁵ Genomics Core Facility, Sloan-Kettering Institute, New York, New York

Requests for reprints: Samuel Singer, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, H1220, New York, NY 10021. Phone: 212-639-2940; Fax: 646-422-2300; E-mail: singers{at}mskcc.org.

Classification of liposarcoma into three biological types encompassing five subtypes, (a) well-differentiated/dedifferentiated, (b) myxoid/round cell, and (c) pleomorphic, based on morphologic features and cytogenetic aberrations, is widely accepted. However, diagnostic discordance remains even among expert sarcoma pathologists. We sought to develop a more systematic approach to liposarcoma classification based on gene expression analysis and to identify subtype-specific differentially expressed genes that may be involved in liposarcoma genesis/progression and serve as potential therapeutic targets. A classifier based on gene expression profiling was able to distinguish between liposarcoma subtypes, lipoma, and normal fat samples. A 142-gene predictor of tissue class was derived to automatically determine the class of an independent validation set of lipomatous samples and shows the feasibility of liposarcoma classification based entirely on gene expression monitoring. Differentially expressed genes for each liposarcoma subtype compared with normal fat were used to identify histology-specific candidate genes with an in-depth analysis of signaling pathways important to liposarcoma pathogenesis and progression in the well-differentiated/dedifferentiated subset. The activation of cell cycle and checkpoint pathways in well-differentiated/dedifferentiated liposarcoma provides several possible novel therapeutic strategies with MDM2 serving as a particularly promising target. We show that Nutlin-3a, an antagonist of MDM2, preferentially induces apoptosis and growth arrest in dedifferentiated liposarcoma cells compared with normal adipocytes. These results support the development of a clinical trial with MDM2 antagonists for liposarcoma subtypes which overexpress MDM2 and show the promise of using this expression dataset for new drug discovery in liposarcoma. [Cancer Res 2007;67(14):6626–36]

This article has been cited by other articles:

				G. Ambrosini, H. S. Cheema, S. Seelman, A. Teed, E. B. Sambol, S. Singer, and G. K. Schwartz Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells Mol. Cancer Ther., April 1, 2008; 7(4): 890 - 896. [Abstract] [Full Text] [PDF]

				I. Matushansky, E. Hernando, N. D. Socci, T. Matos, J. Mills, M. A. Edgar, G. K. Schwartz, S. Singer, C. Cordon-Cardo, and R. G. Maki A Developmental Model of Sarcomagenesis Defines a Differentiation-Based Classification for Liposarcomas Am. J. Pathol., April 1, 2008; 172(4): 1069 - 1080. [Abstract] [Full Text] [PDF]